<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18343" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bisphosphonate</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ganesan</surname>
            <given-names>Kavitha</given-names>
          </name>
          <aff>Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goyal</surname>
            <given-names>Amandeep</given-names>
          </name>
          <aff>University of Kansas Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Roane</surname>
            <given-names>Douglas</given-names>
          </name>
          <aff>Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kavitha Ganesan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amandeep Goyal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Douglas Roane declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18343.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Bisphosphonates define a class of drugs widely indicated since the 1990s to treat osteoporosis both in men and women. Their effectiveness in treating osteoporosis and other conditions is related to their ability to inhibit bone resorption. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the interprofessional team in the treatment of patients using bisphosphonate drugs.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanism of action of bisphosphonates.</p></list-item><list-item><p>Identify the approved indications for bisphosphonate therapy.</p></list-item><list-item><p>Review the potential adverse events for bisphosphonate drugs.</p></list-item><list-item><p>Outline the importance of improving care coordination among the interprofessional team to improve outcomes for patients using bisphosphonate therapy for indicated conditions.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18343&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18343">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18343.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bisphosphonates define a class of drugs widely indicated since the 1990s to treat osteoporosis both in men and women. Their effectiveness in treating osteoporosis and other conditions is related to their ability to inhibit bone resorption.<xref ref-type="bibr" rid="article-18343.r1">[1]</xref><xref ref-type="bibr" rid="article-18343.r2">[2]</xref><xref ref-type="bibr" rid="article-18343.r3">[3]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>FDA-approved indications for bisphosphonates include treatment of osteoporosis in postmenopausal women, osteoporosis in men, glucocorticoid-induced osteoporosis, hypercalcemia of malignancy, Paget disease of the bone, and malignancies with metastasis to the bone.</p>
          </list-item>
          <list-item>
            <p>Non-FDA-approved indications include the treatment of osteogenesis imperfecta in children as well as adults and the prevention of glucocorticoid-induced osteoporosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18343.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bisphosphonates have a structure similar to native pyrophosphate and divide into two groups: nitrogen-containing and non-nitrogen-containing bisphosphonates. Nitrogen-containing bisphosphonates include alendronate, risedronate, ibandronate, pamidronate, and zoledronic acid. Non-nitrogen-containing bisphosphonates include etidronate, clodronate, and tiludronate. All bisphosphonates inhibit bone resorption by attaching to hydroxyapatite binding sites on the bone, particularly in areas with active resorption. As osteoclasts resorb bone, the bisphosphonate embedded in the bone is released and impairs the osteoclast&#x02019;s ability to continue bone resorption.<xref ref-type="bibr" rid="article-18343.r2">[2]</xref><xref ref-type="bibr" rid="article-18343.r4">[4]</xref><xref ref-type="bibr" rid="article-18343.r5">[5]</xref></p>
        <p><bold>Nitrogen-containing bisphosphonates</bold> work by inhibiting farnesyl pyrophosphate synthase, which is important in promoting attachment of the osteoclast to the bone. As a result, the osteoclast detaches from the bone surface, thus inhibiting bone resorption.</p>
        <p><bold>Non-nitrogen-containing bisphosphonates</bold>, on the other hand, are metabolized within the cell to substrates that replace the terminal pyrophosphate moiety of adenosine triphosphate, forming a nonfunctional molecule that competes with adenosine triphosphate in the energy metabolism of the cell. This situation initiates osteoclast apoptosis, which in turn&#x000a0;leads to an overall decrease in bone breakdown.</p>
        <p>Nitrogen-containing bisphosphonates are much more potent antiresorptive agents than non-nitrogen-containing bisphosphonates. Also, non-nitrogen-containing bisphosphonates are found to have a high potential to inhibit bone mineralization and can cause osteomalacia. For this reason, they are no longer in broad-based use.</p>
        <p>
<bold>Efficacy Of Bisphosphonates</bold>
</p>
        <p>All bisphosphonates improve bone mineral density in postmenopausal women with osteoporosis. Alendronate, risedronate, and zoledronic acid decrease the risk of spine, hips, and other nonvertebral fractures.&#x000a0;Ibandronate has not consistently been shown to reduce the risk of hip fractures.</p>
        <list list-type="bullet">
          <list-item>
            <p>Alendronate: Reduces vertebral fracture risk by about 50%, hip fractures, and other nonvertebral fractures by about 30%.<xref ref-type="bibr" rid="article-18343.r6">[6]</xref><xref ref-type="bibr" rid="article-18343.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Risedronate: Reduces vertebral and nonvertebral fractures by about 40%.<xref ref-type="bibr" rid="article-18343.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Zoledronic acid:&#x000a0;Reduces vertebral fracture risk by about 70%, hip fractures, and other nonvertebral fractures by about 35%.<xref ref-type="bibr" rid="article-18343.r9">[9]</xref><xref ref-type="bibr" rid="article-18343.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Ibandronate:&#x000a0;Reduces vertebral fractures by about 50%.&#x000a0;No reduction in risk of nonvertebral fractures.<xref ref-type="bibr" rid="article-18343.r11">[11]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18343.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Alendronate, risedronate, and ibandronate are given orally, most commonly at weekly (alendronate, risedronate) or monthly (risedronate and ibandronate) intervals. The administration of zoledronic acid and pamidronate is intravenous, and there is also an intravenous preparation of ibandronate. Intravenous preparations are beneficial in patients who cannot tolerate oral bisphosphonates or where oral bisphosphonates are contraindicated, such as the presence or history of esophageal stricture.<xref ref-type="bibr" rid="article-18343.r12">[12]</xref><xref ref-type="bibr" rid="article-18343.r13">[13]</xref></p>
        <p>Alendronate is given as 35 mg once weekly for the prophylaxis of osteoporosis in postmenopausal females and as 70 mg once weekly for the treatment of osteoporosis in men and women. For Paget disease of bone in males and females, alendronate is given orally as 40 mg once daily for six months, and risedronate is given 30 mg orally daily for two months. Risedronate is given as 35 mg once weekly and 150 mg once a month. Ibandronate sodium is given as 150 mg orally once a month or 3 mg intravenously every month. Zoledronic acid is given as 4 mg to 5 mg intravenously over at least 15 to 30 minutes every 12 months to treat osteoporosis. Pamidronate is given as 30 mg to 60 mg by slow intravenous infusion every 3 to 6 months for the treatment of hypercalcemia of malignancy, Paget disease, and bone metastasis.</p>
        <p>Patients should receive supplemental calcium 1000 to 1200 mg/day and vitamin D 800 to 1000 international units/day if dietary intake is inadequate. Patients should take oral bisphosphonates as the first&#x000a0;medication in the morning and more than 30 minutes before the first food intake, beverage (except water), or any other medication. Patients should receive instruction to stay upright, not to lay down for at least&#x000a0;thirty minutes&#x000a0;or until&#x000a0;the first food intake of the day to reduce esophageal irritation/ulceration. Milk and milk products, coffee, orange juice, and food may decrease the absorption of oral bisphosphonates.</p>
      </sec>
      <sec id="article-18343.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Bisphosphonates are generally well tolerated, with most adverse effects being non-severe. Reports exist of some serious adverse effects with bisphosphonate use, but these are extremely rare.</p>
        <p>
<bold>1. Gastrointestinal Adverse Effects</bold>
</p>
        <p>All oral bisphosphonates have correlations with upper gastrointestinal adverse effects, including gastrointestinal reflux, esophagitis, esophageal/gastric ulcers, and gastritis. Gastrointestinal side effects are the most common reason for the discontinuation of oral bisphosphonates. The risk increases in patients who take concomitant NSAIDs.<xref ref-type="bibr" rid="article-18343.r14">[14]</xref>&#x000a0;Proper administration of oral bisphosphonates may help to reduce the risk of these gastrointestinal adverse effects.&#x000a0;Clinicians should avoid oral bisphosphonates in patients who are at a higher risk of these gastrointestinal adverse effects, including those who are&#x000a0;not able to sit upright for at least 30 minutes after taking the bisphosphonate, and patients with&#x000a0;esophageal disorders&#x000a0;such as&#x000a0;achalasia, esophageal stricture, Barrett's esophagus, and esophageal varices and patients who have undergone Roux-en-Y gastric bypass. The risk of upper gastrointestinal adverse effects may be slightly lower with risedronate compared to alendronate.&#x000a0; Other gastrointestinal adverse effects include abdominal pain, diarrhea, and constipation, which can occur in up to 5% of patients.</p>
        <p>
<bold>2.&#x000a0;Infusion Reaction</bold>
</p>
        <p>Intravenous bisphosphonates have associations with an infusion/acute phase reaction characterized by flu-like symptoms, fevers, myalgias, arthralgias, and headaches within 1&#x000a0;to 3 days of the infusion.&#x000a0; The symptoms usually respond to acetaminophen or NSAIDs and resolve within a few days.&#x000a0; The risk of the acute phase reaction is highest with the 1st infusion of the intravenous bisphosphonate (up to 30%), and the risk declines significantly with further dosing (less than 7%). This infusion/acute phase reaction is usually mild and self-limiting and does not necessitate discontinuation of the intravenous bisphosphonate therapy.</p>
        <p>
<bold>3. Hypocalcemia</bold>
</p>
        <p>Transient hypocalcemia is a common issue secondary to bisphosphonate use, and the incidence may be as high as 18%. Severe hypocalcemia, however, is rare. Hypocalcemia is more common, secondary to intravenous bisphosphonates, and in patients with an underlying untreated vitamin-D deficiency, hypocalcemia, poor calcium intake, and hypoparathyroidism.<xref ref-type="bibr" rid="article-18343.r15">[15]</xref><xref ref-type="bibr" rid="article-18343.r16">[16]</xref>&#x000a0;Calcium and vitamin-D deficiency require correction before initiating bisphosphonates, especially intravenous bisphosphonates.</p>
        <p>
<bold>4. Arthralgia and Myalgia</bold>
</p>
        <p>Bone, joint, and muscle pain can occur secondary to bisphosphonates.&#x000a0; The symptoms are rare, with an incidence of less than 5%.&#x000a0;Symptoms are usually mild, although there have been reports of severe pain.<xref ref-type="bibr" rid="article-18343.r17">[17]</xref>&#x000a0;The onset of musculoskeletal pain can&#x000a0;occur within days two years after starting bisphosphonates and may not always resolve entirely after discontinuation of bisphosphonates.</p>
        <p>
<bold>5. Ocular Adverse Effects</bold>
</p>
        <p>Rare ocular adverse effects, including uveitis, conjunctivitis, and scleritis, have been reported with all bisphosphonates.<xref ref-type="bibr" rid="article-18343.r18">[18]</xref>&#x000a0;The incidence is infrequent (less than 1%).<xref ref-type="bibr" rid="article-18343.r19">[19]</xref></p>
        <p>
<bold>6. Atypical Femur F</bold>
<bold>ractures</bold>
</p>
        <p>Another rare but serious adverse effect of bisphosphonates is an atypical femoral fracture, typically involving diaphysis or sub-trochanteric region of the femur. Over suppression of bone turnover, pathophysiological alteration in the bone quality, and impairment of fracture repair process, or thought to be responsible for these atypical femur fractures, which are considered stress fractures.&#x000a0;The incidence is&#x000a0;3.2 to 50 cases per 100,000 person-years, and the risk increases with the duration of exposure to bisphosphonates.&#x000a0; Atypical femur fractures are usually not seen within the first five years of bisphosphonate treatment, with most cases reported with more than seven years of bisphosphonate treatment. Initial symptoms are dull aching pain in the groin. Plain X-rays may reveal cortical thickening. Findings of radiographs, especially if early/mild, shall be confirmed by further imaging with&#x000a0;magnetic resonance imaging (MRI) or bone scintigraphy.&#x000a0;Bisphosphonates shall be discontinued in patients who suffer an atypical femur fracture in one leg; if the drug is not stopped, these patients are at higher risk of developing atypical femur fracture in the other leg. Discontinuation of bisphosphonate is associated with a decline in this risk. A drug holiday shall be considered after prolonged exposure to bisphosphonates when clinically appropriate.</p>
        <p>
<bold>7. Osteonecrosis of the Jaw</bold>
</p>
        <p>One of the most severe adverse effects is&#x000a0;bisphosphonate-related osteonecrosis of the jaw (BRONJ).&#x000a0;Most cases of BRONJ have occurred in patients with multiple myeloma and breast cancer treated with high doses of intravenous bisphosphonates. It has also been reported in patients taking bisphosphonates for osteoporosis with an incidence of&#x000a0;approximately 1 in 10,000 to 1 in 100,000.<xref ref-type="bibr" rid="article-18343.r20">[20]</xref>&#x000a0;The risk factors for BRONJ include the use of intravenous bisphosphonates, higher dose and prolonged duration of exposure, pre-existing dental disease, dental implants, dental extraction, and poorly fitting dentures. The use of glucocorticoids and anticancer therapy, history of diabetes, smoking, and cancer may be other risk factors.<xref ref-type="bibr" rid="article-18343.r20">[20]</xref>&#x000a0;A diagnosis of BRONJ must meet all the following criteria:</p>
        <list list-type="bullet">
          <list-item>
            <p>History of treatment with a bisphosphonate;</p>
          </list-item>
          <list-item>
            <p>Those who had more than eight weeks of exposed bone in the maxillofacial region</p>
          </list-item>
          <list-item>
            <p>No radiation therapy to the jaw</p>
          </list-item>
        </list>
        <p>The American Association of Oral and Maxillofacial Surgeons has further defined the stages of Bisphosphonate-related osteonecrosis of the jaw (BRONJ)&#x000a0;as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stage 0:</bold> Indicated by no visible bone but nonspecific symptoms. Common treatment includes Symptomatic treatment and conservative management of underlying dental issues; antibiotics are recommended if the infection is present.</p>
          </list-item>
          <list-item>
            <p><bold>Stage 1</bold>: Indicated by exposed, inflamed necrotic bone without symptoms. Common treatment includes antimicrobial rinses (if the infection is not present).</p>
          </list-item>
          <list-item>
            <p><bold>Stage 2</bold>: Indicated by exposed, necrotic bone with local signs or symptoms of infection. Standard treatment includes symptomatic treatment, antimicrobial rinses, and systemic antibiotics.</p>
          </list-item>
          <list-item>
            <p><bold>Stage 3</bold>: Indicated by exposed, necrotic bone with pain and infection, pathologic fracture, extraoral fistula, and extensive osteolysis. Standard treatment includes symptomatic treatment, systemic antibiotics, and superficial surgical debridement of the necrotic bone.</p>
          </list-item>
        </list>
        <p>If planning an invasive dental procedure, the recommendation is to delay the initiation of bisphosphonate therapy for a few months to allow for healing of the jaw. In patients who have been on bisphosphonates for more than four years and are planning for an invasive dental procedure, recommendations are to stop the bisphosphonate two months before the dental procedure and resume them after jaw healing has been complete. When clinically appropriate, consider a drug holiday after 3&#x000a0;to 5 years of intravenous bisphosphonates and 5 to 10 years of oral bisphosphonates.</p>
      </sec>
      <sec id="article-18343.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to bisphosphonates include:</p>
        <list list-type="order">
          <list-item>
            <p>History of hypersensitivity to the bisphosphonate</p>
          </list-item>
          <list-item>
            <p>Hypocalcemia</p>
          </list-item>
          <list-item>
            <p>Chronic kidney disease with a glomerular filtration rate of less than 30 to 35 mL/min</p>
          </list-item>
          <list-item>
            <p>Avoid oral bisphosphonates in patients with&#x000a0;esophageal disorders such as achalasia, esophageal stricture, esophageal varices, Barrett's esophagus, inability to stand or sit upright for at least 30 minutes, history of bariatric surgery (Roux-en-Y gastric bypass).</p>
          </list-item>
          <list-item>
            <p>History of atypical femur fracture secondary to bisphosphonates</p>
          </list-item>
          <list-item>
            <p>History of&#x000a0;osteonecrosis of the jaw secondary to bisphosphonates</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18343.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Serum calcium, vitamin D, and renal function require baseline monitoring before initiating bisphosphonates. In patients with calcium and/or vitamin D deficiency, the recommendation is to correct the deficiency before starting bisphosphonates. The clinician should take a detailed dental history before initiating bisphosphonates, and therapy initiation should delay if planning an invasive dental procedure in the near future.&#x000a0;Bone mineral density shall be evaluated 1 to 2 years after initiating therapy and every two years or more frequently in patients deemed high risk. Annual measurements of height, weight, serum calcium, 25- hydroxyvitamin D, and an assessment of back pain to check for the development of compression fractures are also necessary.</p>
        <p>In some circumstances, monitoring of biochemical markers of bone resorption such as N-telopeptide of type-1 collagen, C-terminal telopeptide of type 1-collagen and pyridinoline cross-links, and markers of bone formation such as bone-specific alkaline phosphatase, osteocalcin, and N-terminal propeptide of type 1 procollagen before and three months after bisphosphonate initiation can help monitor the effectiveness of the medication in inhibiting bone resorption and measuring compliance. However, these assays are fraught with significant variability within individual patients and poor standardization, so they are not routinely used.</p>
        <p>Alkaline phosphatase should be monitored at 6 to 12 weeks after the treatment initiation in patients with a history of Paget disease and should be repeated at 6-month to 12-month intervals.<xref ref-type="bibr" rid="article-18343.r21">[21]</xref><xref ref-type="bibr" rid="article-18343.r22">[22]</xref></p>
      </sec>
      <sec id="article-18343.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Bisphosphonates are very efficacious in the prevention of fractures in patients with osteoporosis. They are&#x000a0;relatively safe, although&#x000a0;they do have correlations with some rare and serious adverse effects. Patient education is crucial to ensure compliance and effective treatment of osteoporosis. Patients shall receive education to eliminate other risk factors associated with osteoporotic fractures, including smoking cessation, weight-bearing exercises, avoiding excessive alcohol intake, and increasing dairy product intake.<xref ref-type="bibr" rid="article-18343.r23">[23]</xref><xref ref-type="bibr" rid="article-18343.r24">[24]</xref>&#x000a0;The nursing team can assist with patient education and ensuring compliance with medications. Primary care clinicians play the most important role in identifying individuals with a high risk for osteoporosis and fractures&#x000a0;and ensure primary prevention. Pain control and orthotic devices can assist patients who have already developed fractures.<xref ref-type="bibr" rid="article-18343.r25">[25]</xref><xref ref-type="bibr" rid="article-18343.r26">[26]</xref><xref ref-type="bibr" rid="article-18343.r27">[27]</xref>&#x000a0;Referral to specialists such as endocrinologists or rheumatologists shall be considered, especially in complicated cases. These are all examples of the kind of interprofessional teamwork necessary to manage treatment with bisphosphonates successfully. Early detection, patient education, and an interprofessional team approach can ensure better outcomes and prevent fractures in high-risk patients. [Level&#x000a0;5]</p>
      </sec>
      <sec id="article-18343.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18343&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18343">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18343/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18343">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18343.s10">
        <title>References</title>
        <ref id="article-18343.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pautke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Van den Wyngaert</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Niepel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schi&#x000f8;dt</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>69</volume>
            <fpage>177</fpage>
            <page-range>177-187</page-range>
            <pub-id pub-id-type="pmid">30055439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farrell</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Karpeisky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thamm</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Zinnen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bisphosphonate conjugation for bone specific drug targeting.</article-title>
            <source>Bone Rep</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>9</volume>
            <fpage>47</fpage>
            <page-range>47-60</page-range>
            <pub-id pub-id-type="pmid">29992180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Steger</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Niepel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>L&#x000fc;ftner</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.</article-title>
            <source>Prostate Cancer Prostatic Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>461</fpage>
            <page-range>461-472</page-range>
            <pub-id pub-id-type="pmid">29988100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frediani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giusti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dalle Carbonare</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Malavolta</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cantarini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saviola</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Molfetta</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clodronate in the management of different musculoskeletal conditions.</article-title>
            <source>Minerva Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>109</volume>
            <issue>4</issue>
            <fpage>300</fpage>
            <page-range>300-325</page-range>
            <pub-id pub-id-type="pmid">29947493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Di Girolamo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Necozione</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Continenza</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Cutilli</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5&#x000a0;years of experience.</article-title>
            <source>Musculoskelet Surg</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>47</fpage>
            <page-range>47-53</page-range>
            <pub-id pub-id-type="pmid">29948937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cummings</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Applegate</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Barrett-Connor</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Musliner</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Palermo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prineas</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>LaCroix</surname>
                <given-names>AZ</given-names>
              </name>
            </person-group>
            <article-title>Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.</article-title>
            <source>JAMA</source>
            <year>1998</year>
            <month>Dec</month>
            <day>23-30</day>
            <volume>280</volume>
            <issue>24</issue>
            <fpage>2077</fpage>
            <page-range>2077-82</page-range>
            <pub-id pub-id-type="pmid">9875874</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Karpf</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Cauley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Nevitt</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Genant</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Haskell</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Torner</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Quandt</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Reiss</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Ensrud</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.</article-title>
            <source>Lancet</source>
            <year>1996</year>
            <month>Dec</month>
            <day>07</day>
            <volume>348</volume>
            <issue>9041</issue>
            <fpage>1535</fpage>
            <page-range>1535-41</page-range>
            <pub-id pub-id-type="pmid">8950879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harris</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Genant</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>McKeever</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hangartner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chesnut</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eriksen</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Hoseyni</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Axelrod</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.</article-title>
            <source>JAMA</source>
            <year>1999</year>
            <month>Oct</month>
            <day>13</day>
            <volume>282</volume>
            <issue>14</issue>
            <fpage>1344</fpage>
            <page-range>1344-52</page-range>
            <pub-id pub-id-type="pmid">10527181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Black</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Delmas</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Boonen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cauley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cosman</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lakatos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mautalen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mesenbrink</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Caminis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rosario-Jansen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Krasnow</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hue</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Sellmeyer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eriksen</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Cummings</surname>
                <given-names>SR</given-names>
              </name>
              <collab>HORIZON Pivotal Fracture Trial</collab>
            </person-group>
            <article-title>Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>May</month>
            <day>03</day>
            <volume>356</volume>
            <issue>18</issue>
            <fpage>1809</fpage>
            <page-range>1809-22</page-range>
            <pub-id pub-id-type="pmid">17476007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lyles</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Col&#x000f3;n-Emeric</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Magaziner</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Adachi</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pieper</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Mautalen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hyldstrup</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Recknor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nordsletten</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lavecchia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mesenbrink</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hodgson</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Abrams</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Orloff</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Horowitz</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Eriksen</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Boonen</surname>
                <given-names>S</given-names>
              </name>
              <collab>HORIZON Recurrent Fracture Trial</collab>
            </person-group>
            <article-title>Zoledronic acid and clinical fractures and mortality after hip fracture.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Nov</month>
            <day>01</day>
            <volume>357</volume>
            <issue>18</issue>
            <fpage>1799</fpage>
            <page-range>1799-809</page-range>
            <pub-id pub-id-type="pmid">17878149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chesnut</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Skag</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Recker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stakkestad</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hoiseth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Felsenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gilbride</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schimmer</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Delmas</surname>
                <given-names>PD</given-names>
              </name>
              <collab>Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)</collab>
            </person-group>
            <article-title>Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.</article-title>
            <source>J Bone Miner Res</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>1241</fpage>
            <page-range>1241-9</page-range>
            <pub-id pub-id-type="pmid">15231010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>US Preventive Services Task Force</collab>
              <name>
                <surname>Curry</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Krist</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Caughey</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Doubeni</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Epling</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kemper</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kubik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Landefeld</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mangione</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Phipps</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Pignone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Jun</month>
            <day>26</day>
            <volume>319</volume>
            <issue>24</issue>
            <fpage>2521</fpage>
            <page-range>2521-2531</page-range>
            <pub-id pub-id-type="pmid">29946735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viswanathan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Berkman</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cullen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Nicholson</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Kahwati</surname>
                <given-names>LC</given-names>
              </name>
            </person-group>
            <article-title>Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Jun</month>
            <day>26</day>
            <volume>319</volume>
            <issue>24</issue>
            <fpage>2532</fpage>
            <page-range>2532-2551</page-range>
            <pub-id pub-id-type="pmid">29946734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graham</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Malaty</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Alendronate and naproxen are synergistic for development of gastric ulcers.</article-title>
            <source>Arch Intern Med</source>
            <year>2001</year>
            <month>Jan</month>
            <day>08</day>
            <volume>161</volume>
            <issue>1</issue>
            <fpage>107</fpage>
            <page-range>107-10</page-range>
            <pub-id pub-id-type="pmid">11146706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schussheim</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Hypocalcemia associated with alendronate.</article-title>
            <source>Ann Intern Med</source>
            <year>1999</year>
            <month>Feb</month>
            <day>16</day>
            <volume>130</volume>
            <issue>4 Pt 1</issue>
            <fpage>329</fpage>
            <pub-id pub-id-type="pmid">10068397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency.</article-title>
            <source>N Engl J Med</source>
            <year>2003</year>
            <month>Apr</month>
            <day>10</day>
            <volume>348</volume>
            <issue>15</issue>
            <fpage>1503</fpage>
            <page-range>1503-4</page-range>
            <pub-id pub-id-type="pmid">12686715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wysowski</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Alendronate and risedronate: reports of severe bone, joint, and muscle pain.</article-title>
            <source>Arch Intern Med</source>
            <year>2005</year>
            <month>Feb</month>
            <day>14</day>
            <volume>165</volume>
            <issue>3</issue>
            <fpage>346</fpage>
            <page-range>346-7</page-range>
            <pub-id pub-id-type="pmid">15710802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pazianas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Eiken</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Brixen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Abrahamsen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.</article-title>
            <source>J Bone Miner Res</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3</issue>
            <fpage>455</fpage>
            <page-range>455-63</page-range>
            <pub-id pub-id-type="pmid">23044864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Bolland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nisa</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Al-Abuwsi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Horne</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>McGhee</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial.</article-title>
            <source>Osteoporos Int</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>499</fpage>
            <page-range>499-503</page-range>
            <pub-id pub-id-type="pmid">25187119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanley</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Felsenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>McCauley</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>O'Ryan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Ruggiero</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Taguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tetradis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Guise</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eastell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Morin</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Masri</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Obermayer-Pietsch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Langdahl</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Al Dabagh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Davison</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kendler</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>S&#x000e1;ndor</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Josse</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Bhandari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>El Rabbany</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pierroz</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Sulimani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Compston</surname>
                <given-names>J</given-names>
              </name>
              <collab>International Task Force on Osteonecrosis of the Jaw</collab>
            </person-group>
            <article-title>Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.</article-title>
            <source>J Bone Miner Res</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-23</page-range>
            <pub-id pub-id-type="pmid">25414052</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aparecida Cariolatto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carelli</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Campos Moreira</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Pietrobon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonilauri Ferreira</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for the Prevention of Bisphosphonate-Related Osteonecrosis of the Jaw: A Systematic Review.</article-title>
            <source>J Evid Based Dent Pract</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>2</issue>
            <fpage>142</fpage>
            <page-range>142-152</page-range>
            <pub-id pub-id-type="pmid">29747794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simm</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Biggin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zacharin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rodda</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Tham</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Siafarikas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jefferies</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hofman</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Woodhead</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Brookes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lafferty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Munns</surname>
                <given-names>CF</given-names>
              </name>
              <collab>APEG Bone Mineral Working Group</collab>
            </person-group>
            <article-title>Consensus guidelines on the use of bisphosphonate therapy in children and adolescents.</article-title>
            <source>J Paediatr Child Health</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>54</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-233</page-range>
            <pub-id pub-id-type="pmid">29504223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albergaria</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Chalem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Messina</surname>
                <given-names>OD</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>RMR</given-names>
              </name>
              <name>
                <surname>Vidal</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title>Consensus statement: osteoporosis prevention and treatment in Latin America-current structure and future directions.</article-title>
            <source>Arch Osteoporos</source>
            <year>2018</year>
            <month>Aug</month>
            <day>24</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <pub-id pub-id-type="pmid">30143914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nuti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Checchia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Di Munno</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Dominguez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Falaschi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fiore</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Iolascon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Maggi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Michieli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Migliaccio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Minisola</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rossini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sessa</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tarantino</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Toselli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Isaia</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the management of osteoporosis and fragility fractures.</article-title>
            <source>Intern Emerg Med</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>85</fpage>
            <page-range>85-102</page-range>
            <pub-id pub-id-type="pmid">29948835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Clinical effect of early bisphosphonate treatment for pyogenic vertebral osteomyelitis with osteoporosis: An analysis by the Cox proportional hazard model.</article-title>
            <source>Spine J</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>19</volume>
            <issue>3</issue>
            <fpage>418</fpage>
            <page-range>418-429</page-range>
            <pub-id pub-id-type="pmid">30172897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rouach</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Goldshtein</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Catane</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chodick</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Iton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Exposure to alendronate is associated with a lower risk of bone metastases in osteoporotic women with early breast cancer.</article-title>
            <source>J Bone Oncol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>12</volume>
            <fpage>91</fpage>
            <page-range>91-95</page-range>
            <pub-id pub-id-type="pmid">30148062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18343.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis: A meta-analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>96</volume>
            <issue>52</issue>
            <fpage>e9534</fpage>
            <pub-id pub-id-type="pmid">29384970</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
